-

SMLR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Semler Scientific, Inc. Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Semler Scientific, Inc. (“Semler” or the “Company”) (NASDAQ:SMLR) securities during the period of March 10, 2021 through April 15, 2025, inclusive (“the Class Period”).

If you suffered a loss on your Semler investments, you have until October 28, 2025 to request lead plaintiff appointment. Follow the link below for more information:

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Happened?

On February 28, 2025, Semler filed its Form 10-K with the SEC and therein, disclosed that the Company received an initial civil investigative demand from the U.S. Department of Justice in July 2017 regarding Semler’s claims for reimbursement related to the QuantaFlo device. Semler received subsequent requests for information in February 2019, December 2021, April 2022, and April 2023. In February 2025, Semler participated in settlement discussions with the DOJ, which were unsuccessful. The Company disclosed that “there is a risk that DOJ will file a complaint or complaint in intervention in a civil False Claims Act lawsuit seeking damages.” On this news, the price of Semler shares declined by $4.03 per share, or approximately 9.39%, from $42.92 per share on February 28, 2025 to close at $38.89 on March 3, 2025.

Then, on April 15, 2025, Semler Scientific revealed that it “reached agreement in principle on payment of $29.75 million to settle all claims (which amount excludes any potential relator counsel fees that may also be payable),” according to the complaint. On this news, the price of Semler shares declined by $3.40 per share, or approximately 9.9%, from $34.40 per share on April 15, 2025 to close at $31.00 on April 16, 2025.

What Is The Lawsuit About?

The lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose a material investigation by the United States Department of Justice (the "DOJ") into violations of the False Claims Act, while discussing possible violations of the False Claims (and aggressive DOJ enforcement thereof) in hypothetical terms. When the true details entered the market, the lawsuit claims that investors suffered damages.

What Should I Do?

If you purchased or otherwise acquired Semler securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:SMLR

Release Versions

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclos...

IBRX ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of ImmunityBio, Inc. Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) securities during the period of January 19, 2026 through March 24, 2026, inclusive (“the Class Period”). If you suffered a loss on your ImmunityBio investments, you have until May 26, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERE...

PYPL DEADLINE NOTICE: PayPal Holdings, Inc. Investors Encouraged to Contact Kirby McInerney LLP By April 20, 2026

NEW YORK--(BUSINESS WIRE)--If you suffered a loss on your investment inPayPal Holdings, Inc. (“PayPal” or the “Company”) (NASDAQ:PYPL), contact Lauren Molinaro by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until April 20, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff ove...
Back to Newsroom